ES2109882A1 - Clorhidrato de 6-hidroxifenil)-3-(4-(piperidinotetoxi)benzoil)benzo(b)tiofeno - Google Patents

Clorhidrato de 6-hidroxifenil)-3-(4-(piperidinotetoxi)benzoil)benzo(b)tiofeno

Info

Publication number
ES2109882A1
ES2109882A1 ES09501774A ES9501774A ES2109882A1 ES 2109882 A1 ES2109882 A1 ES 2109882A1 ES 09501774 A ES09501774 A ES 09501774A ES 9501774 A ES9501774 A ES 9501774A ES 2109882 A1 ES2109882 A1 ES 2109882A1
Authority
ES
Spain
Prior art keywords
antiestrogenic
benzothiophenyl
compounds
benzothiophenyl compounds
piperidinoethoxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
ES09501774A
Other languages
English (en)
Other versions
ES2109882B1 (es
Inventor
Labell Elizabet Smith
Wayne Douglas Luke
Iii John Mcneill Mcgill
Randal Scot Miller
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26976194&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2109882(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US08/308,325 external-priority patent/US5629425A/en
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Publication of ES2109882A1 publication Critical patent/ES2109882A1/es
Application granted granted Critical
Publication of ES2109882B1 publication Critical patent/ES2109882B1/es
Anticipated expiration legal-status Critical
Revoked legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
    • C07D333/54—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C07D333/56—Radicals substituted by oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

CLORHIDRATO DE 6-HIDROXIFENIL)-3-[4-(PIPERIDINOETOXI)BENZOIL]BENZO[B]TIOFENO. LA PRESENTE INVENCION ESTA DIRIGIDA A UNA NUEVA FORMA CRISTALINA, NO SOLVATADA DE CLORHIDRATO DE 6-HIDROXI-2-(4-HIDROXIFENIL)-3-[4-2(PIPERIDINOETOXI)BENZOIL]BENZO[B]TIOFENO, QUE ESTA SUSTANCIALMENTE LIBRE DE CLOROBENCENO Y DE IMPUREZAS ORGANOALUMINICAS O SALES DE ALUMINIO; ASI COMO TAMBIEN SUSTANCIALMENTE LIBRE DE OLOR, POR LO QUE ES PARTICULARMENTE UTIL PARA SU USO EN LA FABRICACION DE COMPOSICIONES FARMACEUTICAS. EN EL NUEVO PROCEDIMIENTO DE PREPARACION SE USAN CATALIZADORES DE BORO, EN LA ETAPA DE ACILACION DE UN 6-ALCOXI-2-ALCOXIFENIL-BENZOTIOFENO. A DICHA ETAPA DE ACILACION LE SUCEDE UNA ETAPA DE DESALQUILACION DE LOS GRUPOS FENOLICOS, AISLANDOSE UN SOLVATO CRISTALINO DE LA FORMULA I. EL SOLVATO CRISTALINO DEL COMPUESTO DE FORMULA I SE HACE REACCIONAR, EN METANOL, O EN UNA MEZCLA DE METANOL Y AGUA, CON UNA BASE; Y FINALMENTE SE EXTRAE COMO UN DISOLVENTE HIDROCARBONADO ALIFATICO EN FORMA DE BASE LIBRE EL COMPUESTO CRISTALINO NO SOLVATADO, O BIEN, SE TRATA CON ACIDO CLORHIDRICO PARA OBTENER EL CLORHIDRATO DEL COMPUESTO CRISTALINO NO SOLVATADO.
ES09501774A 1994-09-19 1995-09-13 Clorhidrato de 6-hidroxifenil)-3-(4-(piperidinoetoxi) benzoil)benzo(b)tiofeno Revoked ES2109882B1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/308,325 US5629425A (en) 1994-09-19 1994-09-19 Haloalkyl hemisolvates of 6-hydroxy-2-(4-hydroxyphenyl)-3-[4-piperidinoethoxy)-benzoyl]benzo[b]thiophene
US42791495A 1995-04-26 1995-04-26

Publications (2)

Publication Number Publication Date
ES2109882A1 true ES2109882A1 (es) 1998-01-16
ES2109882B1 ES2109882B1 (es) 1998-08-16

Family

ID=26976194

Family Applications (2)

Application Number Title Priority Date Filing Date
ES09501774A Revoked ES2109882B1 (es) 1994-09-19 1995-09-13 Clorhidrato de 6-hidroxifenil)-3-(4-(piperidinoetoxi) benzoil)benzo(b)tiofeno
ES009501775A Expired - Fee Related ES2129293B1 (es) 1994-09-19 1995-09-13 "sintesis de 3-(4-(2-aminoetoxi)-benzoil)-2-aril-6-hidroxibenzo (b) tiofenos"

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES009501775A Expired - Fee Related ES2129293B1 (es) 1994-09-19 1995-09-13 "sintesis de 3-(4-(2-aminoetoxi)-benzoil)-2-aril-6-hidroxibenzo (b) tiofenos"

Country Status (50)

Country Link
US (4) US6472531B1 (es)
JP (2) JPH08193081A (es)
KR (2) KR100381346B1 (es)
CN (2) CN1068324C (es)
AP (1) AP754A (es)
AT (2) AT407988B (es)
AU (3) AU692907B2 (es)
BE (2) BE1009626A3 (es)
BG (1) BG62793B1 (es)
BR (2) BR9504059A (es)
CA (2) CA2158399C (es)
CH (3) CH691478A5 (es)
CO (2) CO4410190A1 (es)
CZ (2) CZ292007B6 (es)
DE (3) DE19534744A1 (es)
DK (4) DK175903B1 (es)
EE (1) EE03386B1 (es)
EG (1) EG23763A (es)
ES (2) ES2109882B1 (es)
FI (2) FI121424B (es)
FR (2) FR2732020B1 (es)
GB (2) GB2293602B (es)
GE (1) GEP19991821B (es)
GR (2) GR1002709B (es)
HR (2) HRP950483B1 (es)
HU (2) HU227683B1 (es)
IE (2) IE950722A1 (es)
IL (3) IL115314A (es)
IS (1) IS1788B (es)
IT (2) IT1277602B1 (es)
LU (2) LU88661A1 (es)
LV (2) LV11177B (es)
MY (1) MY116371A (es)
NL (2) NL1001194C2 (es)
NO (2) NO308107B1 (es)
NZ (2) NZ280027A (es)
OA (1) OA10406A (es)
PE (2) PE14796A1 (es)
PL (2) PL187686B1 (es)
PT (2) PT101771B (es)
RO (2) RO115260B1 (es)
RS (2) RS49513B (es)
SE (2) SE509265C2 (es)
SI (2) SI9500293A (es)
SK (1) SK283502B6 (es)
TR (1) TR199501136A2 (es)
TW (1) TW412534B (es)
UA (2) UA44240C2 (es)
UY (1) UY24040A1 (es)
WO (1) WO1996009045A1 (es)

Families Citing this family (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE38968E1 (en) 1992-07-28 2006-02-07 Eli Lilly And Company Methods for inhibiting bone loss using 6-hydroxy-2-(4-hydroxyphenyl)-benzo[b]thien-3-yl-4-[2-(piperidin-1-yl) ethoxyphenylimethanone hydrochloride
USRE39049E1 (en) 1992-07-28 2006-03-28 Eli Lilly And Company Methods for inhibiting bone loss
TW366342B (en) * 1992-07-28 1999-08-11 Lilly Co Eli The use of 2-phenyl-3-aroylbenzothiophenes in inhibiting bone loss
US5478847A (en) 1994-03-02 1995-12-26 Eli Lilly And Company Methods of use for inhibiting bone loss and lowering serum cholesterol
CO4410190A1 (es) * 1994-09-19 1997-01-09 Lilly Co Eli 3-[4-(2-AMINOETOXI)-BENZOIL]-2-ARIL-6-HIDROXIBENZO [b] TIOFENO CRISTALINO
EA001257B1 (ru) * 1996-03-26 2000-12-25 Эли Лилли Энд Компани Бензотиофены, содержащие их фармацевтические композиции и способы лечения патологических состояний с их использованием
US6458811B1 (en) * 1996-03-26 2002-10-01 Eli Lilly And Company Benzothiophenes formulations containing same and methods
ZA992858B (en) 1996-10-30 1999-07-29 Lilly Co Eli Methods of preventing breast cancer.
CA2236254A1 (en) * 1997-04-30 1998-10-30 David Warren Hoard Process for preparing benzo¬b|thiophenes
CN1250563C (zh) 1999-05-04 2006-04-12 斯特拉坎有限公司 雄激素糖苷及其产生雄性征的活性
AU2002230409A1 (en) * 2000-11-27 2002-06-03 Eli Lilly And Company Process for preparing 3-aryl-benzo(b)thiophenes
EP2316468A1 (en) 2002-02-22 2011-05-04 Shire LLC Delivery system and methods for protecting and administering dextroamphetamine
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
EP1832583A1 (en) 2002-09-30 2007-09-12 A/S GEA Farmaceutisk Fabrik Novel raloxifene sulphuric acid addition salts and/or solvates thereof, and pharmaceutical compositions comprising these
US6861422B2 (en) 2003-02-26 2005-03-01 Boehringer Ingelheim Pharma Gmbh & Co. Kg Dihydropteridinones, processes for preparing them and their use as pharmaceutical compositions
US20060106010A1 (en) * 2003-05-27 2006-05-18 Black Larry J Methods for inhibiting bone loss
US7501426B2 (en) 2004-02-18 2009-03-10 Boehringer Ingelheim International Gmbh 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
DE102004029784A1 (de) 2004-06-21 2006-01-05 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue 2-Benzylaminodihydropteridinone, Verfahren zur deren Herstellung und deren Verwendung als Arzneimittel
DE102004030502A1 (de) 2004-06-24 2006-01-12 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Imidazole und Triazole, deren Herstellung und Verwendung als Arzneimittel
DE102004033670A1 (de) 2004-07-09 2006-02-02 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Pyridodihydropyrazinone, Verfahren zu Ihrer Herstellung und Ihre Verwendung als Arzneimittel
US20060035903A1 (en) 2004-08-14 2006-02-16 Boehringer Ingelheim International Gmbh Storage stable perfusion solution for dihydropteridinones
US20060058311A1 (en) 2004-08-14 2006-03-16 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation
US7759485B2 (en) 2004-08-14 2010-07-20 Boehringer Ingelheim International Gmbh Process for the manufacture of dihydropteridinones
US7728134B2 (en) 2004-08-14 2010-06-01 Boehringer Ingelheim International Gmbh Hydrates and polymorphs of 4[[(7R)-8-cyclopentyl-7-ethyl-5,6,7,8-tetrahydro-5-methyl-6-oxo-2-pteridinyl]amino]-3-methoxy-N-(1-methyl-4-piperidinyl)-benzamide, process for their manufacture and their use as medicament
US20060074088A1 (en) 2004-08-14 2006-04-06 Boehringer Ingelheim International Gmbh Dihydropteridinones for the treatment of cancer diseases
EP1630163A1 (de) 2004-08-25 2006-03-01 Boehringer Ingelheim Pharma GmbH & Co.KG Dihydropteridinonderivative, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel
DK1797038T3 (da) 2004-09-29 2012-09-03 Bayer Pharma AG Termodynamisk stabil form af bay 43-9006-tosylat
US20060068010A1 (en) * 2004-09-30 2006-03-30 Stephen Turner Method for improving the bioavailability of orally delivered therapeutics
DE102004054054A1 (de) 2004-11-05 2006-05-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
DE102004058337A1 (de) 2004-12-02 2006-06-14 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung von annelierten Piperazin-2-on Derivaten
DE102005035891A1 (de) 2005-07-30 2007-02-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
US7439358B2 (en) 2006-02-08 2008-10-21 Boehringer Ingelheim International Gmbh Specific salt, anhydrous and crystalline form of a dihydropteridione derivative
PE20080251A1 (es) 2006-05-04 2008-04-25 Boehringer Ingelheim Int Usos de inhibidores de dpp iv
EP2540725A1 (de) 2006-05-04 2013-01-02 Boehringer Ingelheim International GmbH Polymorphe von 1-((4-Methyl-chinazolin-2-yl)methyl)-3-methyl-7-(2-butin-1-yl)-8-(3-(R)-amino-piperidin-1-yl)xanthin
EP1852108A1 (en) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG DPP IV inhibitor formulations
AR062927A1 (es) 2006-10-11 2008-12-17 Bayer Healthcare Ag 4- [4-( [ [ 4- cloro-3-( trifluorometil) fenil) carbamoil] amino] -3- fluorofenoxi) -n- metilpiridin-2- carboxamida monohidratada
US8344149B2 (en) * 2006-10-17 2013-01-01 Cipla Limited Crystalline form of benzothiophene compound and process for preparation thereof
US20080103295A1 (en) * 2006-10-25 2008-05-01 David Losan Ho Process for the preparation of sucrose-6-ester by esterification in the presence of solid superacid catalyst
US8258291B2 (en) * 2006-10-25 2012-09-04 Mamtek International Limited Process for the preparation of sucralose by the chlorination of sugar with triphosgene (BTC)
DE102007032451B4 (de) 2007-07-12 2010-09-30 Icfs Gmbh Verfahren zur Herstellung von aromatischen Ketonen
US20090023799A1 (en) * 2007-07-20 2009-01-22 George Laurence CRYSTALS OF (2-AMINO-4,5,6,7-TETRAHYDROBENZO[b]THIEN-3-YL)(4-CHLOROPHENYL)METHANONE
WO2009019205A1 (en) 2007-08-03 2009-02-12 Boehringer Ingelheim International Gmbh Crystalline form of a dihydropteridione derivative
EP2242483B1 (en) * 2007-12-21 2013-02-20 Synthon B.V. Raloxifene composition
PE20091730A1 (es) 2008-04-03 2009-12-10 Boehringer Ingelheim Int Formulaciones que comprenden un inhibidor de dpp4
US20110088613A1 (en) * 2008-06-09 2011-04-21 Massimo Ferrari Process for controlling the growth of a raloxifene hydrochloride crystal
UY32030A (es) 2008-08-06 2010-03-26 Boehringer Ingelheim Int "tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
BRPI0916997A2 (pt) 2008-08-06 2020-12-15 Boehringer Ingelheim International Gmbh Inibidor de dpp-4 e seu uso
CN102149407A (zh) 2008-09-10 2011-08-10 贝林格尔.英格海姆国际有限公司 治疗糖尿病和相关病症的组合疗法
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
CN102256976A (zh) 2008-12-23 2011-11-23 贝林格尔.英格海姆国际有限公司 有机化合物的盐形式
AR074990A1 (es) 2009-01-07 2011-03-02 Boehringer Ingelheim Int Tratamiento de diabetes en pacientes con un control glucemico inadecuado a pesar de la terapia con metformina
WO2011000581A2 (en) 2009-07-02 2011-01-06 Synthon B.V. Raloxifene composition
EP2314581B1 (en) 2009-10-23 2012-07-25 Hexal AG A process for preparing benzo[b]thiophene derivatives
KR20240090632A (ko) 2009-11-27 2024-06-21 베링거 인겔하임 인터내셔날 게엠베하 리나글립틴과 같은 ｄｐｐ－ｉｖ 억제제를 사용한 유전자형 검사된 당뇨병 환자의 치료
WO2011099942A1 (en) 2010-02-09 2011-08-18 Silverstone Pharma New addition salts of raloxifene, process for the preparation thereof and use thereof in therapy
CN102946875A (zh) 2010-05-05 2013-02-27 贝林格尔.英格海姆国际有限公司 组合疗法
WO2011161161A1 (en) 2010-06-24 2011-12-29 Boehringer Ingelheim International Gmbh Diabetes therapy
US8546566B2 (en) 2010-10-12 2013-10-01 Boehringer Ingelheim International Gmbh Process for manufacturing dihydropteridinones and intermediates thereof
IT1403083B1 (it) * 2010-10-25 2013-10-04 Fidia Farmaceutici Nuova forma polimorfa di raloxifene cloridrato
AR083878A1 (es) 2010-11-15 2013-03-27 Boehringer Ingelheim Int Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento
US9358233B2 (en) 2010-11-29 2016-06-07 Boehringer Ingelheim International Gmbh Method for treating acute myeloid leukemia
US9370535B2 (en) 2011-05-17 2016-06-21 Boehringer Ingelheim International Gmbh Method for treatment of advanced solid tumors
US8883800B2 (en) 2011-07-15 2014-11-11 Boehringer Ingelheim International Gmbh Substituted quinazolines, the preparation thereof and the use thereof in pharmaceutical compositions
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
JP6218811B2 (ja) 2012-05-14 2017-10-25 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｓｉｒｓ及び／又は敗血症の治療に用いるｄｐｐ−４阻害薬としてのキサンチン誘導体
JP6224084B2 (ja) 2012-05-14 2017-11-01 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 糸球体上皮細胞関連障害及び／又はネフローゼ症候群の治療に用いるｄｐｐ−４阻害薬としてのキサンチン誘導体
WO2013174767A1 (en) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
IN2013MU00665A (es) 2013-03-05 2015-07-03 Cipla Ltd
EP3024464A1 (en) 2013-07-26 2016-06-01 Boehringer Ingelheim International GmbH Treatment of myelodysplastic syndrome
EP3110449B1 (en) 2014-02-28 2023-06-28 Boehringer Ingelheim International GmbH Medical use of a dpp-4 inhibitor
US9867831B2 (en) 2014-10-01 2018-01-16 Boehringer Ingelheim International Gmbh Combination treatment of acute myeloid leukemia and myelodysplastic syndrome
CN104496963A (zh) * 2014-12-02 2015-04-08 千辉药业（安徽）有限责任公司 一种盐酸雷洛昔芬的制备方法
CN109310697A (zh) 2016-06-10 2019-02-05 勃林格殷格翰国际有限公司 利格列汀和二甲双胍的组合
KR102815172B1 (ko) * 2020-02-25 2025-05-29 엘지전자 주식회사 히트펌프 및 그 동작방법

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2096608A (en) * 1981-04-03 1982-10-20 Lilly Co Eli A process for preparing acylated benzothiophenes
GB2097392A (en) * 1981-04-03 1982-11-03 Lilly Co Eli Process for preparing 3-(4-aminoethylbenzoyl) benzo-(bthiophenes
GB2097788A (en) * 1981-04-03 1982-11-10 Lilly Co Eli Benzothiophene compounds and process for preparing them
US4418068A (en) * 1981-04-03 1983-11-29 Eli Lilly And Company Antiestrogenic and antiandrugenic benzothiophenes

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3869485A (en) * 1969-09-25 1975-03-04 Allied Chem Preparation of acid chlorides with phosgene in the presence of a catalyst
GB1456323A (en) * 1974-06-06 1976-11-24 Labaz Benzothiophenes process for preparing them and pharmaceutical compositions containing the same
US4133814A (en) 1975-10-28 1979-01-09 Eli Lilly And Company 2-Phenyl-3-aroylbenzothiophenes useful as antifertility agents
US4358593A (en) * 1981-04-03 1982-11-09 Eli Lilly And Company Process for preparing 3-(4-aminoethoxybenzoyl)benzo[b]thiophenes
ZA822247B (en) 1981-04-03 1983-11-30 Lilly Co Eli Benzothiophene compounds and process for preparing them
US4380635A (en) * 1981-04-03 1983-04-19 Eli Lilly And Company Synthesis of acylated benzothiophenes
DE4117512A1 (de) * 1991-05-25 1992-11-26 Schering Ag 2-phenylbenzo(b)furane und -thiophene, verfahren zu deren herstellung und diese enthaltende pharmazeutische praeparate
JP3157882B2 (ja) * 1991-11-15 2001-04-16 帝国臓器製薬株式会社 新規なベンゾチオフエン誘導体
US5169860A (en) 1992-03-13 1992-12-08 Eli Lilly And Company Antitumor compositions and methods of treatment
TW383306B (en) * 1992-12-22 2000-03-01 Lilly Co Eli New use of 2-phenyl-3-aroylbenzothiophenes in lowering serum cholesterol
DE69405491T2 (de) * 1993-06-24 1998-02-19 Lilly Co Eli Antiöstrogene 2-Phenyl-3-Aroylbenzothiophene als hypoglykämische Mittel
US6756388B1 (en) 1993-10-12 2004-06-29 Pfizer Inc. Benzothiophenes and related compounds as estrogen agonists
US5523416A (en) 1994-07-22 1996-06-04 Eli Lilly And Company Process for preparing 3-(4-aminoethoxy-benzoyl) benzo (B)-thiophenes
CO4410190A1 (es) * 1994-09-19 1997-01-09 Lilly Co Eli 3-[4-(2-AMINOETOXI)-BENZOIL]-2-ARIL-6-HIDROXIBENZO [b] TIOFENO CRISTALINO

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2096608A (en) * 1981-04-03 1982-10-20 Lilly Co Eli A process for preparing acylated benzothiophenes
GB2097392A (en) * 1981-04-03 1982-11-03 Lilly Co Eli Process for preparing 3-(4-aminoethylbenzoyl) benzo-(bthiophenes
GB2097788A (en) * 1981-04-03 1982-11-10 Lilly Co Eli Benzothiophene compounds and process for preparing them
US4418068A (en) * 1981-04-03 1983-11-29 Eli Lilly And Company Antiestrogenic and antiandrugenic benzothiophenes

Also Published As

Publication number Publication date
BE1009625A3 (fr) 1997-06-03
DK175886B1 (da) 2005-05-23
LV11177A (lv) 1996-04-20
LV11177B (en) 1996-08-20
ITMI951936A1 (it) 1997-03-15
ITMI951935A0 (it) 1995-09-15
GB2293382B (en) 1998-08-19
LV11178B (en) 1996-08-20
AT502957A1 (de) 2007-06-15
IL115315A (en) 1999-09-22
NO953657L (no) 1996-03-20
DE19534744A1 (de) 1996-03-21
CZ240295A3 (en) 1996-04-17
HUT74178A (en) 1996-11-28
SE9503213D0 (sv) 1995-09-15
PE32796A1 (es) 1996-08-07
GB2293382A (en) 1996-03-27
CO4410190A1 (es) 1997-01-09
DE19534745A1 (de) 1996-04-04
PE14796A1 (es) 1996-05-19
FI954402L (fi) 1996-03-20
IL115314A (en) 2000-02-29
JPH08176147A (ja) 1996-07-09
CZ290343B6 (cs) 2002-07-17
NO953658L (no) 1996-03-20
KR960010634A (ko) 1996-04-20
SE509265C2 (sv) 1998-12-21
YU61395A (sh) 1998-09-18
LU88660A1 (fr) 1996-07-15
CA2158400C (en) 2006-10-24
IL115314A0 (en) 1996-05-14
WO1996009045A1 (en) 1996-03-28
JPH08193081A (ja) 1996-07-30
CH691594A5 (de) 2001-08-31
HRP950482B1 (en) 2007-04-30
CN1127253A (zh) 1996-07-24
HU9502723D0 (en) 1995-11-28
NZ280027A (en) 1997-05-26
CN1068324C (zh) 2001-07-11
AU3173195A (en) 1996-04-04
JP2860071B2 (ja) 1999-02-24
DK2797A (da) 1997-01-09
NL1001194A1 (nl) 1996-03-19
ES2109882B1 (es) 1998-08-16
GB2293602B (en) 1998-05-06
FR2724655B1 (fr) 1997-11-14
GR1002709B (el) 1997-06-04
BR9504059A (pt) 1996-09-24
PT101770B (pt) 1997-04-30
CH691125A5 (de) 2001-04-30
MY116371A (en) 2004-01-31
US20020173645A1 (en) 2002-11-21
NO953657D0 (no) 1995-09-15
SI9500293A (en) 1996-06-30
CA2158399A1 (en) 1996-03-20
RS49578B (sr) 2007-04-10
US6399778B1 (en) 2002-06-04
SI9500292A (en) 1996-06-30
FI954403A0 (fi) 1995-09-18
PT101771B (pt) 1997-04-30
TR199501136A2 (tr) 1996-06-21
CN1075069C (zh) 2001-11-21
UA44240C2 (uk) 2002-02-15
SK283502B6 (sk) 2003-08-05
DE19534745B4 (de) 2004-06-09
DK175887B1 (da) 2005-05-23
NL1001196C2 (nl) 1997-04-04
EE03386B1 (et) 2001-04-16
GR1002697B (el) 1997-05-22
GEP19991821B (en) 1999-11-05
CZ292007B6 (cs) 2003-07-16
GB9519032D0 (en) 1995-11-15
BG62793B1 (bg) 2000-08-31
ES2129293A1 (es) 1999-06-01
AU3718695A (en) 1996-04-09
CA2158399C (en) 2001-03-20
PL310517A1 (en) 1996-04-01
US6472531B1 (en) 2002-10-29
PT101771A (pt) 1996-04-30
CO4410191A1 (es) 1997-01-09
CH691478A5 (de) 2001-07-31
ES2129293B1 (es) 2000-01-16
NO313996B1 (no) 2003-01-13
AP754A (en) 1999-07-22
IT1277601B1 (it) 1997-11-11
OA10406A (en) 2001-12-05
KR100367376B1 (ko) 2003-03-06
HRP950483B1 (en) 2003-02-28
EE9700055A (et) 1997-08-15
SE520721C2 (sv) 2003-08-12
AP9700938A0 (en) 1997-04-30
IE950721A1 (en) 1996-03-20
CA2158400A1 (en) 1996-03-20
BG101242A (en) 1998-03-31
CZ240395A3 (en) 1996-04-17
CN1132205A (zh) 1996-10-02
GB9519028D0 (en) 1995-11-15
PL310518A1 (en) 1996-04-01
TW412534B (en) 2000-11-21
HUT75033A (en) 1997-03-28
HK1019009A1 (en) 2000-01-14
FR2724655A1 (fr) 1996-03-22
RS49513B (sr) 2006-10-27
KR960010637A (ko) 1996-04-20
IE80883B1 (en) 1999-05-19
RO115260B1 (ro) 1999-12-30
GB2293602A (en) 1996-04-03
DE19549755B4 (de) 2005-05-04
ITMI951935A1 (it) 1997-03-15
ITMI951936A0 (it) 1995-09-15
FI954402A0 (fi) 1995-09-18
AU692907B2 (en) 1998-06-18
AU691955B2 (en) 1998-05-28
IT1277602B1 (it) 1997-11-11
HRP950482A2 (en) 1998-02-28
UY24040A1 (es) 1996-03-07
FI121424B (fi) 2010-11-15
FI112226B (fi) 2003-11-14
LV11178A (lv) 1996-04-20
IL125283A (en) 2001-06-14
DK102895A (da) 1996-03-20
SE9503213L (sv) 1996-03-20
HU227683B1 (en) 2011-11-28
HRP950483A2 (en) 1997-10-31
DK102795A (da) 1996-03-20
UA42716C2 (uk) 2001-11-15
US5731327A (en) 1998-03-24
ATA154295A (de) 2000-12-15
IE950722A1 (en) 1996-03-20
BR9504060A (pt) 1996-09-24
PL182450B1 (pl) 2002-01-31
PT101770A (pt) 1996-04-30
BE1009626A3 (fr) 1997-06-03
NO308107B1 (no) 2000-07-24
AT407988B (de) 2001-07-25
NZ280028A (en) 1997-05-26
HU9502721D0 (en) 1995-11-28
SE9503214D0 (sv) 1995-09-15
IS4446A (is) 1997-03-18
HU225417B1 (en) 2006-11-28
FR2732020A1 (fr) 1996-09-27
EG23763A (en) 2007-08-08
IS1788B (is) 2001-11-28
YU61495A (sh) 1998-05-15
SK23397A3 (en) 1997-08-06
DK175897B1 (da) 2005-05-30
KR100381346B1 (ko) 2004-04-13
NO953658D0 (no) 1995-09-15
DK2897A (da) 1997-01-09
FR2732020B1 (fr) 1997-11-14
DK175903B1 (da) 2005-06-06
IL115315A0 (en) 1995-12-31
SE9503214L (sv) 1996-03-20
NL1001194C2 (nl) 1997-04-04
LU88661A1 (fr) 1996-07-15
AU3173095A (en) 1996-04-04
RO115259B1 (ro) 1999-12-30
NL1001196A1 (nl) 1996-03-19
FI954403A7 (fi) 1996-03-20
PL187686B1 (pl) 2004-09-30

Similar Documents

Publication Publication Date Title
ES2109882A1 (es) Clorhidrato de 6-hidroxifenil)-3-(4-(piperidinotetoxi)benzoil)benzo(b)tiofeno
MY112481A (en) Synthesis of 3-[4-(2-aminoethoxy)-benzoyl] -2-aryl-6-hydroxybenzo [b] thiophenes
GR3036028T3 (en) 2-amino-3-aroyl-benzo beta thiophenes and method of making the same
ZA9093B (en) Substituted indole,benzofuran and benzothiophene derivatives as 5-lipoxygenase inhibitors
MY131787A (en) An improved process for preparing 3-(4-aminoethoxy- benzoyl) benzo (b) - thiophenes
PE16799A1 (es) Procedimiento para la sintesis de benzotiofenos
JO1890B1 (en) New pharmaceutical product
JO1894B1 (en) New pharmaceutical product
ECSP951462A (es) SINTESIS DE 3- [4--(2- AMINO-ETOXI)BENZOIL] -2- ARIL-8-HIDROXIBENZO [b] TIOFENOS (CASO X- 9295A)
ECSP951461A (es) SINTESIS DE 3- {4-(2- AMINOETOXI) BENZOIL]-2-ARIL-6- HIDROXIBENZO {b] TIOFENOS (CASO X- 9295B)
NZ310215A (en) Process for the synthesis of 2-aryl-benzo[b]thiophenes
IL122378A0 (en) Process for the synthesis of benzo Úb¾ thiophenes
FR2783383B1 (fr) Publiphone equipe de moyens d'acces a des reseaux informatiques
MX9709130A (es) Proceso para la sintesis de derivados del acido vinilsulfenico.
TJ399B (en) A novel crystalline form of 6-hydroxy -3-(4-Ä2-(piperidin-1-yl) ethoxyÜ- phenoxy) -2-(4-methoxyphenyl) benzo ÄBÜ thiophene hydrochloride.
TJ398B (en) A novel crystalline form of 6-hydroxy -3-(4-Ä2-(piperidin-1-yl) ethoxyÜ-phenoxy) -2-(4-methoxyphenyl) benzo ÄbÜ thiophene hydrochloride.
MX9709672A (es) Proceso para la sintesis de benzo[b]tiofenos.

Legal Events

Date Code Title Description
EC2A Search report published

Date of ref document: 19980116

Kind code of ref document: A1

Effective date: 19980116

RL2A Annulment by court decision

Effective date: 20100317

RL2A Annulment by court decision

Effective date: 20100317